JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1992; 19:842-850
© 1992 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fonarow, G.
Right arrow Articles by Albanese, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fonarow, G.
Right arrow Articles by Albanese, E

Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial

GC Fonarow, C Chelimsky-Fallick, LW Stevenson, M Luu, MA Hamilton, JD Moriguchi, JH Tillisch, JA Walden, and E Albanese

Ahmanson-University of California, Los Angeles.

To compare the benefit of angiotensin-converting enzyme inhibition and direct vasodilation on the prognosis of advanced heart failure, 117 patients evaluated for cardiac transplantation who had severe symptoms and abnormal hemodynamic status at rest were randomized to treatment with either captopril or hydralazine plus isosorbide dinitrate (Hy-C Trial). Comparable hemodynamic effects of the two regimens were sought by titrating vasodilator doses to match the hemodynamic status achieved with nitroprusside and diuretic agents, attempting to achieve a pulmonary capillary wedge pressure of 15 mm Hg and a systemic vascular resistance of 1,200 dynes.s.cm-5. Treatment with the alternate vasodilator was started because of poor hemodynamic response or side effects (40% of patients in the captopril group and 22% in the hydralazine group). Adequate hemodynamic response in patients with a serum sodium level less than 135 mg/dl was more likely with hydralazine than with captopril (71% vs. 33%, p = 0.04). Isosorbide dinitrate was prescribed in 88% of the hydralazine-treated patients and 84% of the captopril-treated patients. The hemodynamic improvements from each regimen were equivalent. After 8 +/- 7 months of follow-up, the actuarial 1-year survival rate was 81% in the captopril-treated patients and 51% in the hydralazine-treated patients (p = 0.05). The improved survival with captopril resulted from a lower rate of sudden death, which occurred in only 3 of 44 captopril-treated patients compared with 17 of 60 hydralazine-treated patients (p = 0.01). In the subset of patients who continued treatment with the initial vasodilator, results were similar to those for the entire treatment group.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
H. E. Verdejo, P. F. Castro, R. Concepcion, M. A. Ferrada, M. A. Alfaro, M. E. Alcaino, C. C. Deck, and R. C. Bourge
Comparison of a Radiofrequency-Based Wireless Pressure Sensor to Swan-Ganz Catheter and Echocardiography for Ambulatory Assessment of Pulmonary Artery Pressure in Heart Failure
J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2375 - 2382.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C. Funck-Brentano
Beta-blockade in CHF: from contraindication to indication
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
The ESCAPE Investigators and ESCAPE Study Coordina
Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: The ESCAPE Trial
JAMA, October 5, 2005; 294(13): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. A. Reiffel
Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S45 - S58.
[Abstract] [PDF]


Home page
Am. J. Clin. Nutr.Home page
K. Kalantar-Zadeh, K. C Abbott, A. K Salahudeen, R. D Kilpatrick, and T. B Horwich
Survival advantages of obesity in dialysis patients
Am. J. Clinical Nutrition, March 1, 2005; 81(3): 543 - 554.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa
Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1171 - 1178.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H. Montgomery, S. Humphries, and S. Danilov
Is genotype or phenotype the better tool for investigating the role of ACE in human cardiovascular disease?
Eur. Heart J., July 2, 2002; 23(14): 1083 - 1086.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. Johnson, T. Omland, C. Hall, C. Lucas, O. L. Myking, C. Collins, M. Pfeffer, J.-L. Rouleau, and L. W. Stevenson
Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure
J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1623 - 1629.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. Nohria, E. Lewis, and L. W. Stevenson
Medical Management of Advanced Heart Failure
JAMA, February 6, 2002; 287(5): 628 - 640.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. B. Horwich, G. C. Fonarow, M. A. Hamilton, W. R. MacLellan, M. A. Woo, and J. H. Tillisch
The relationship between obesity and mortality in patients with heart failure
J. Am. Coll. Cardiol., September 1, 2001; 38(3): 789 - 795.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A Ohlsson, S.H Kubo, D Steinhaus, D.T Connelly, S Adler, C Bitkover, R Nordlander, L Ryden, and T Bennett
Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study
Eur. Heart J., June 1, 2001; 22(11): 942 - 954.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
P. Colson, F. Ryckwaert, and P. Coriat
Renin Angiotensin System Antagonists and Anesthesia
Anesth. Analg., November 1, 1999; 89(5): 1143 - 1143.
[Full Text] [PDF]


Home page
HeartHome page
J C Vaile, J Fletcher, W A Littler, J H Coote, and J N Townend
Angiotensin II modulates cardiovascular autonomic control in the absence of baroreflex loading
Heart, August 1, 1998; 80(2): 127 - 133.
[Abstract] [Full Text]


Home page
HeartHome page
British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and endorsed by the British Diabetic Association
Joint British recommendations on prevention of coronary heart disease in clinical practice
Heart, July 1, 1998; 80(90002): 1S - 29.
[Full Text]


Home page
Arch Intern MedHome page
P. Jaagosild, N. V. Dawson, C. Thomas, N. S. Wenger, J. Tsevat, W. A. Knaus, R. M. Califf, L. Goldman, H. Vidaillet, A. F. Connors Jr, et al.
Outcomes of Acute Exacerbation of Severe Congestive Heart Failure: Quality of Life, Resource Use, and Survival
Arch Intern Med, May 25, 1998; 158(10): 1081 - 1089.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
V. S. Chekanov, S. Deshpande, and D. H. Schmidt
CARDIOMYOPLASTY COMBINED WITH IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR
J. Thorac. Cardiovasc. Surg., September 1, 1997; 114(3): 489 - 491.
[Full Text]


Home page
CirculationHome page
A. E. Steimle, L. W. Stevenson, C. Chelimsky-Fallick, G. C. Fonarow, M. A. Hamilton, J. D. Moriguchi, A. Kartashov, and J. H. Tillisch
Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure
Circulation, August 19, 1997; 96(4): 1165 - 1172.
[Abstract] [Full Text]


Home page
CirculationHome page
L. W. Stevenson, G. Couper, B. Natterson, G. Fonarow, M. A. Hamilton, M. Woo, and J. W. Creaser
Target Heart Failure Populations for Newer Therapies
Circulation, November 1, 1995; 92(9): 174 - 181.
[Abstract] [Full Text]


Home page
CirculationHome page
G. M. Eaton, R. J. Cody, E. Nunziata, and P. F. Binkley
Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure
Circulation, August 1, 1995; 92(3): 555 - 561.
[Abstract] [Full Text]


Home page
HypertensionHome page
J. N. Townend, M. Al-Ani, J. N. West, W. A. Littler, and J. H. Coote
Modulation of Cardiac Autonomic Control in Humans by Angiotensin II
Hypertension, June 1, 1995; 25(6): 1270 - 1275.
[Abstract] [Full Text]


Home page
CirculationHome page
L. Nascimben, J. Friedrich, R. Liao, P. Pauletto, A. C. Pessina, and J. S. Ingwall
Enalapril Treatment Increases Cardiac Performance and Energy Reserve Via the Creatine Kinase Reaction in Myocardium of Syrian Myopathic Hamsters With Advanced Heart Failure
Circulation, March 15, 1995; 91(6): 1824 - 1833.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1992 by the American College of Cardiology Foundation.